[
  {
    "ts": null,
    "headline": "AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE",
    "summary": "Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
    "url": "https://finnhub.io/api/news?id=6f3eb8cd363a6d043e3953f90391db9adce233af53a7132413fce5d2ea350762",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731099600,
      "headline": "AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE",
      "id": 131234225,
      "image": "https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
      "url": "https://finnhub.io/api/news?id=6f3eb8cd363a6d043e3953f90391db9adce233af53a7132413fce5d2ea350762"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial",
    "summary": "A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its primary endpoint.",
    "url": "https://finnhub.io/api/news?id=e1ea455443bdc6d865ea825d66f9053fba1c387e749e0537cc4505fef17bdaf7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731077567,
      "headline": "AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial",
      "id": 131223582,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/11/shutterstock_2267695157-scaled.jpg",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its primary endpoint.",
      "url": "https://finnhub.io/api/news?id=e1ea455443bdc6d865ea825d66f9053fba1c387e749e0537cc4505fef17bdaf7"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis",
    "summary": "AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) The data showed that Tezspire demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. Also Read: Amgen/AstraZeneca’s Asthma Drug Tezspire Vs. Sanofi/Regeneron’s Blockbuster Dupixent",
    "url": "https://finnhub.io/api/news?id=e8b0db08a0490848a76776fa63a60acc3ec16490086f9a583b2cd2bb67b0c557",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731073628,
      "headline": "AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis",
      "id": 131223585,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) The data showed that Tezspire demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. Also Read: Amgen/AstraZeneca’s Asthma Drug Tezspire Vs. Sanofi/Regeneron’s Blockbuster Dupixent",
      "url": "https://finnhub.io/api/news?id=e8b0db08a0490848a76776fa63a60acc3ec16490086f9a583b2cd2bb67b0c557"
    }
  },
  {
    "ts": null,
    "headline": "Amgen : Army Veteran Mike Berke Helping Lead the Charge in Research Automation",
    "summary": "For 20 years, former Green Beret Mike Berke, a director of Engineering and member of Amgen's Veteran Employee Network , has led the charge for Amgen's Research & Automation Technologies. This team...",
    "url": "https://finnhub.io/api/news?id=fff993165ab346dfdbc9d794ba17ff06041e41290fb2c0500bb3e890791ade7e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731065656,
      "headline": "Amgen : Army Veteran Mike Berke Helping Lead the Charge in Research Automation",
      "id": 131221114,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "For 20 years, former Green Beret Mike Berke, a director of Engineering and member of Amgen's Veteran Employee Network , has led the charge for Amgen's Research & Automation Technologies. This team...",
      "url": "https://finnhub.io/api/news?id=fff993165ab346dfdbc9d794ba17ff06041e41290fb2c0500bb3e890791ade7e"
    }
  },
  {
    "ts": null,
    "headline": "TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS",
    "summary": "Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial demonstrated patients treated with TEZSPIRE® (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. The safety profile and tolerability of TEZSPIRE in the trial were consistent with the k",
    "url": "https://finnhub.io/api/news?id=940d0d93ca10f917fc03039a8659f0f099518e112b7a70a2d399c54023d1705f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731049200,
      "headline": "TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS",
      "id": 131225338,
      "image": "https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial demonstrated patients treated with TEZSPIRE® (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. The safety profile and tolerability of TEZSPIRE in the trial were consistent with the k",
      "url": "https://finnhub.io/api/news?id=940d0d93ca10f917fc03039a8659f0f099518e112b7a70a2d399c54023d1705f"
    }
  }
]